I-Mab Biopharma Receives Strategic Investment and Announces $65 Million Offering
Shanghai, China — I-Mab Biopharma, a clinical-stage biopharmaceutical company based in Shanghai, China, has recently made significant strides in its financial and strategic endeavors. The company, which operates in the health care sector with a focus on developing novel biologics for cancers and autoimmune disorders, has announced a strategic investment from Everest Medicines and the pricing of a $65 million offering of American Depositary Shares (ADS).
Strategic Investment by Everest Medicines
On August 1, 2025, Everest Medicines announced a substantial investment in I-Mab Biopharma, committing US$30.9 million in cash. This investment, combined with the shares already held by Everest, will result in a pro forma ownership of 16.1% in I-Mab. This strategic partnership is expected to leverage the complementary strengths of both companies. I-Mab’s innovative 4-1BB receptor targeting platform and bispecific antibody pipeline align well with Everest’s existing mRNA cancer vaccines and in vivo CAR-T platform. The collaboration aims to accelerate the development and global expansion of pipeline products, benefiting from I-Mab’s clinical translational capabilities in the U.S. and Everest’s clinical expertise in Asia.
In a recent Phase 1b trial, I-Mab’s Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% when used in combination with immunotherapy for first-line gastric cancers. This promising result underscores the potential of I-Mab’s pipeline and the strategic value of the partnership with Everest.
New Investors Join the Offering
In addition to Everest, new investors participating in this offering include Janus Henderson Investors, Adage Capital Partners LP, Woodline Partners, and Exome Asset Management. This influx of investment is expected to bolster I-Mab’s financial position and support its ongoing clinical and commercial development efforts.
$65 Million ADS Offering
Simultaneously, I-Mab Biopharma announced the pricing of a $65 million underwritten offering of American Depositary Shares. This offering is part of the company’s strategy to raise capital to support its clinical development programs and expand its global reach. The successful pricing of this offering reflects investor confidence in I-Mab’s pipeline and its potential to address significant unmet medical needs.
Company Overview
I-Mab Biopharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China. The company is dedicated to discovering, developing, and commercializing novel biologics to address significant unmet medical needs, particularly in the areas of cancers and autoimmune disorders. I-Mab operates in the health care sector and is listed on the Nasdaq with a market capitalization of approximately $163.8 million as of July 30, 2025. The company’s recent financial activities, including the strategic investment and ADS offering, are pivotal steps in its mission to bring innovative therapies to market.
These developments mark a significant milestone for I-Mab Biopharma as it continues to advance its clinical programs and expand its presence in the global biopharmaceutical landscape.